behavior/neurological
• JZL184-treated mice exhibit reduced responses to the antinociceptive and hypothermic effects of delta9-tetrahydrocannabinol (THC) and WIN55,22-2 (a full cannabinoid receptor agonist) compared with similarly treated wild-type mice
• however, mice exhibit normal CB1 agonist-induced catalepsy
|
• JZL184-treated mice exhibit reduced responses to the antinociceptive effects of delta9-tetrahydrocannabinol (THC) and WIN55,22-2 (a full cannabinoid receptor agonist) compared with similarly treated wild-type mice
|
hypoalgesia
(
J:165274
)
• mice exhibit antinociception in an acute thermal tail-withdrawal test and reduced mechanical and cold allodynia in the chronic constrictive injury of the sciatic nerve (CCI) model compared with wild-type mice
• however, treatment with JZL184 restores normal tail-withdrawal latencies in a tail-immersion test for thermal nociception
|
• hot and cold
|
homeostasis/metabolism
• JZL184-treated mice exhibit reduced responses to the hypothermic effects of delta9-tetrahydrocannabinol (THC) and WIN55,22-2 (a full cannabinoid receptor agonist) compared with similarly treated wild-type mice
|
• mice exhibit a decrease in C20:4 arachidonic acid free fatty acids in the brain compared with wild-type mice
|
• JZL184-treated mice exhibit reduced responses to the antinociceptive and hypothermic effects of delta9-tetrahydrocannabinol (THC) and WIN55,22-2 (a full cannabinoid receptor agonist) compared with similarly treated wild-type mice
|